BeyondSpring
Market Cap
US$468.8m
Last Updated
2020/05/27 09:14 UTC
Data Sources
Company Financials +
Executive Summary
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies.
Snowflake Analysis
Adequate balance sheet with weak fundamentals.
Share Price & News
How has BeyondSpring's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BYSI's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-5.7%
BYSI
-0.9%
US Biotechs
2.5%
US Market
1 Year Return
6.1%
BYSI
24.5%
US Biotechs
8.4%
US Market
Return vs Industry: BYSI underperformed the US Biotechs industry which returned 23.8% over the past year.
Return vs Market: BYSI exceeded the US Market which returned 4.6% over the past year.
Shareholder returns
| BYSI | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.7% | -0.9% | 2.5% |
| 30 Day | 26.7% | 3.2% | 5.1% |
| 90 Day | 3.8% | 13.6% | 2.0% |
| 1 Year | 6.1%6.1% | 25.7%24.5% | 10.9%8.4% |
| 3 Year | -51.8%-51.8% | 32.2%27.8% | 30.5%21.9% |
| 5 Year | n/a | -3.4%-9.2% | 56.9%39.2% |
Price Volatility Vs. Market
How volatile is BeyondSpring's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
How BeyondSpring Inc. (NASDAQ:BYSI) Can Impact Your Portfolio Volatility5 months ago | Simply Wall St
Could BeyondSpring Inc.'s (NASDAQ:BYSI) Investor Composition Influence The Stock Price?7 months ago | Simply Wall St
What Kind Of Share Price Volatility Should You Expect For BeyondSpring Inc. (NASDAQ:BYSI)?Valuation
Is BeyondSpring undervalued compared to its fair value and its price relative to the market?
15.48x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BYSI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BYSI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BYSI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BYSI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BYSI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BYSI is overvalued based on its PB Ratio (15.5x) compared to the US Biotechs industry average (3.8x).
Next Steps
Future Growth
How is BeyondSpring forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
55.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BYSI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BYSI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BYSI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if BYSI's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if BYSI's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BYSI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has BeyondSpring performed over the past 5 years?
-25.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BYSI is currently unprofitable.
Growing Profit Margin: BYSI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BYSI is unprofitable, and losses have increased over the past 5 years at a rate of -25.6% per year.
Accelerating Growth: Unable to compare BYSI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BYSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: BYSI has a negative Return on Equity (-129.56%), as it is currently unprofitable.
Next Steps
Financial Health
How is BeyondSpring's financial position?
Financial Position Analysis
Short Term Liabilities: BYSI's short term assets ($40.9M) exceed its short term liabilities ($10.1M).
Long Term Liabilities: BYSI's short term assets ($40.9M) exceed its long term liabilities ($3.4M).
Debt to Equity History and Analysis
Debt Level: BYSI's debt to equity ratio (4.7%) is considered satisfactory.
Reducing Debt: BYSI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BYSI has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BYSI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 40.1% each year
Next Steps
Dividend
What is BeyondSpring's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BYSI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BYSI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BYSI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BYSI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BYSI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.1yrs
Average management tenure
CEO
Lan Huang (48yo)
5.5yrs
Tenure
Dr. Lan Huang, Ph.D., co-founded BeyondSpring Pharmaceuticals, Inc. in 2013 and serves as its Chairman and Chief Executive Officer. Dr. Huang Co-founded BeyondSpring Inc. and has been its Chairman and Chi ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.5yrs | no data | 37.18% $174.3m | |
| Chief Financial Officer | 2.17yrs | no data | 0.56% $2.6m | |
| Chief Operating Officer | 1.75yrs | no data | no data | |
| Chief Scientific Officer | 2.08yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Senior Vice President of Human Resources | 0.50yr | no data | no data | |
| Executive VP of Research & Development | 0.33yr | no data | 0.79% $3.7m | |
| Chief Scientific Officer Emeritus & Senior Advisor | no data | no data | 0.072% $336.2k | |
| Chief Regulatory Officer | no data | no data | 0.00049% $2.3k | |
| Controller | no data | no data | no data |
2.1yrs
Average Tenure
58yo
Average Age
Experienced Management: BYSI's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.5yrs | no data | 37.18% $174.3m | |
| Executive VP of Research & Development | 0.33yr | no data | 0.79% $3.7m | |
| Independent Director | 3.58yrs | no data | 0.017% $80.1k | |
| Independent Director | 2.33yrs | no data | 0.014% $65.9k | |
| Member of Scientific Advisors & Principal Investigators Board | no data | no data | no data | |
| Independent Director | 4yrs | no data | 2.47% $11.6m | |
| Independent Director | 4yrs | no data | 0.015% $71.0k | |
| Independent Director | 3.58yrs | no data | 0.017% $80.1k | |
| Member of Scientific Advisors & Principal Investigators Board | no data | no data | no data | |
| Member of Scientific Advisors & Principal Investigators Board | no data | no data | no data |
3.6yrs
Average Tenure
52.5yo
Average Age
Experienced Board: BYSI's board of directors are considered experienced (3.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.3%.
Top Shareholders
Company Information
BeyondSpring Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: BeyondSpring Inc.
- Ticker: BYSI
- Exchange: NasdaqCM
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$468.757m
- Shares outstanding: 27.89m
- Website: https://www.beyondspringpharma.com
Number of Employees
Location
- BeyondSpring Inc.
- 28 Liberty Street
- 39th Floor
- New York
- New York
- 10005
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BYSI | NasdaqCM (Nasdaq Capital Market) | Yes | Ordinary Shares | US | USD | Mar 2017 |
Biography
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company’s lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab for the treatment of NSCLC; and programmed cell death protein 1 and CTLA-4 antibodies to treat small cell lung cancer. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the University of Washington and the Fred Hutchinson Cancer Research Center. The company was founded in 2010 and is headquartered in New York, New York.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/27 09:14 |
| End of Day Share Price | 2020/05/26 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.